DAC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
However, introducing salinity into the fluid raises the critical point to higher temperatures and pressures. The critical point of seawater (3.2 wt. % NaCl) is 407 °C (765 °F) and 298.5 bars, corresponding to a depth of ~2,960 m (9,710 ft) below sea level. Accordingly, if a hydrothermal fluid with a salinity of 3.2 wt. % NaCl vents above 407 °C (765 °F) and 298.5 bars, it is supercritical. Furthermore, the salinity of vent fluids have been shown to vary widely due to phase separation in the crust. The critical point for lower salinity fluids is at lower temperature and pressure conditions than that for seawater, but higher than that for pure water. For example, a vent fluid with a 2.24 wt. % NaCl salinity has the critical point at 400 °C (752 °F) and 280.5 bars. Thus, water emerging from the hottest parts of some hydrothermal vents can be a supercritical fluid, possessing physical properties between those of a gas and those of a liquid.Examples of supercritical venting are found at several sites. Sister Peak (Comfortless Cove Hydrothermal Field, 4°48′S 12°22′W, depth 2,996 m or 9,829 ft) vents low salinity phase-separated, vapor-type fluids. Sustained venting was not found to be supercritical but a brief injection of 464 °C (867 °F) was well above supercritical conditions. A nearby site, Turtle Pits, was found to vent low salinity fluid at 407 °C (765 °F), which is above the critical point of the fluid at that salinity.
In 1947, Raleigh citizens adopted a council–manager form of government, which is still the city's current form of government. The Dorton Arena, a 7,610-seat multi-purpose arena designed by Matthew Nowicki, was opened in 1952 on the grounds of the North Carolina State Fair. It was listed in the National Register of Historic Places in 1973.
There is no disease-modifying treatments proven to cure Alzheimer's disease, and because of this, AD research has focused on interventions to prevent the onset and progression. There is no evidence that supports any particular measure in preventing AD, and studies of measures to prevent the onset or progression have produced inconsistent results. Epidemiological studies have proposed relationships between an individual's likelihood of developing AD and modifiable factors, such as medications, lifestyle, and diet. There are some challenges in determining whether interventions for AD act as a primary prevention method, preventing the disease itself, or a secondary prevention method, identifying the early stages of the disease. These challenges include duration of intervention, different stages of disease at which intervention begins, and lack of standardization of inclusion criteria regarding biomarkers specific for AD. Further research is needed to determine factors that can help prevent AD.
Sources: en.wikipedia.org
titration Also titrimetry or volumetric analysis. A laboratory method of quantitative chemical analysis that is used to determine the concentration of an identified analyte. The procedure involves preparing a particular reagent as a standard solution of known concentration and volume (called the titrant or titrator) and allowing it to react with a solution of the analyte (called the titrand) to determine the latter's concentration.
The United States has maintained a space program since the late 1950s, beginning with the establishment of the National Aeronautics and Space Administration (NASA) in 1958. In 1961, the United States became the second country (after the Soviet Union) to successfully launch a human into space. NASA's Apollo program (1961–1972) achieved the first crewed Moon landing with the 1969 Apollo 11 mission; it remains one of the agency's most significant milestones. Other major endeavors by NASA include the Space Shuttle program (1981–2011), the Voyager program (1972–present), the Hubble and James Webb space telescopes (launched in 1990 and 2021, respectively), and the multi-mission Mars Exploration Program (Spirit, Opportunity, Curiosity, and Perseverance). NASA is one of five agencies collaborating on the International Space Station (ISS); U.S. contributions to the ISS include several modules, including Destiny (2001), Harmony (2007), and Tranquility (2010), as well as ongoing logistical and operational support. The United States private sector dominates the global commercial spaceflight industry. Prominent American spaceflight contractors include Blue Origin, Boeing, Lockheed Martin, Northrop Grumman, and SpaceX. NASA programs such as the Commercial Crew Program, Commercial Resupply Services, Commercial Lunar Payload Services, and NextSTEP have facilitated growing private-sector involvement in American spaceflight.
=== Assistive technologies === Assistive technologies are products designed to provide accessibility to individuals who have physical or cognitive problems or disabilities. They aim to improve the quality of life with assistive technologies. The range of assistive technologies is broad, ranging from low-tech solutions to physical hardware, to technical devices. There are four areas of assistive technologies, which include visual impairment, hearing impairment, physical limitations, cognitive limitations. There are many benefits of assistive technologies. They enable individuals to care for themselves, work, study, access information easily, improve independence and communication, and lastly participate fully in community life.
Sources: en.wikipedia.org
Telisotuzumab vedotin, sold under the brand name Emrelis, is an antibody drug conjugate used for the treatement of non-small cell lung cancer. Telisotuzumab vedotin is a c-Met-directed antibody and microtubule inhibitor conjugate. It was developed by AbbVie. The most common adverse reactions include peripheral neuropathy, fatigue, decreased appetite, and peripheral edema. The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, increased glucose, increased alanine aminotransferase, increased gamma glutamyl transferase, decreased phosphorus, decreased sodium, decreased hemoglobin, and decreased calcium. Telisotuzumab vedotin was approved for medical use in the United States in May 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
The adaptor hypothesis was framed to explain how information could be extracted from a nucleic acid and used to put together a string of amino acids in a specific sequence, that sequence being determined by the nucleotide sequence of the nucleic acid (DNA or RNA) template. Crick proposed that each amino acid is first attached to its own specific "adaptor" piece of nucleic acid (in an enzyme-catalysed reaction). The order of assembly of the amino acids is then determined by a specific recognition between the adaptor and the nucleic acid which is serving as the informational template. In this way the amino acids could be lined up by the template in a specific order. Coupling between adjacent amino acids would then lead to the synthesis of a polypeptide whose sequence is determined by the template nucleic acid.
=== Transvaal stayaway: 5–6 November 1984 === On 27 October, at a meeting of 37 political, civic, and labour organisations in Johannesburg, COSAS reiterated a prior call for workers to support the youth's demands and oppose the heavy-handed state response to the uprising. The meeting resolved to form an ad hoc joint committee, the Transvaal Regional Stay-Away Committee, which would coordinate a two-day stay-away. In a major development, trade unions – notably the largest union, the Federation of South African Trade Unions, but also the Council of Mining Unions and the Metal and Allied Workers' Union – overcame their prevailing tendency towards to political "absenteeism" and participated. The stay-away, held on 5 to 6 November, was a resounding success. On competing estimates, between 40 per cent and 60 per cent of workers in Johannesburg did not attend work on the first day, and the government said that 250,000 students had not attended school. On the second day, the figures were even higher, including an estimated 90 per cent of workers in Vaal, 85 per cent on the East Rand, and 66 per cent in Soweto. That evening, Sasol, the state-owned energy corporation, announced that it had fired 90 per cent of its workforce – 6,000 workers – for participating. The work-stoppage was accompanied in some areas by further violence and arson, met by police tear gas and rubber bullets; ten people were reported killed on the first day and a further seven on the second.
mistranslation The insertion of an incorrect amino acid in a growing peptide chain during translation, i.e. the inclusion of any amino acid that is not the one specified by a particular codon in an mRNA transcript. Mistranslation may originate from a mischarged transfer RNA or from a malfunctioning ribosome.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.